LIVIVO - Search results -

Search results

Result 1 - 10 of total 288

Search options

Article ; Online: Retinopathy in a Patient With IgM MGUS: Causal Association or an Epiphenomenon?

Ntanasis-Stathopoulos, Ioannis / Kastritis, Efstathios / Tzartos, John / Terpos, Evangelos / Dimopoulos, Meletios A / Gavriatopoulou, Maria

In vivo (Athens, Greece)

2024 Volume 38, Issue 2, Page(s) 954–957

Abstract: Background/aim: The presence of a monoclonal gammopathy of undetermined significance (MGUS) even in small amounts may trigger tissue damage through immunological or other mechanisms, irrespective of the potential for malignant transformation. The aim of ...

Abstract	Background/aim: The presence of a monoclonal gammopathy of undetermined significance (MGUS) even in small amounts may trigger tissue damage through immunological or other mechanisms, irrespective of the potential for malignant transformation. The aim of the study was to present a case of monoclonal gammopathy of clinical significance with ocular manifestations and discuss relevant literature. Case report: In our case, a patient presented with vision disturbances that was eventually attributed to the underlying IgM MGUS after extensive workup to exclude other potential etiologies. The patient showed a clinical response with the fixed-duration DRC (dexamethasone, rituximab, cyclophosphamide) regimen that persisted for at least 1.5 years. Herein, we present, in detail, the patient management and discuss the underlying pathophysiology of this rare entity with few available published data in this field. Conclusion: A high level of clinical suspicion is necessary in order to detect the association between MGUS and a clinical sign or symptom that cannot be attributed elsewhere.
MeSH term(s)	Humans ; Monoclonal Gammopathy of Undetermined Significance/complications ; Monoclonal Gammopathy of Undetermined Significance/diagnosis ; Cyclophosphamide ; Immunoglobulin M ; Cell Transformation, Neoplastic ; Retinal Diseases
Chemical Substances	Cyclophosphamide (8N3DW7272P) ; Immunoglobulin M
Language	English
Publishing date	2024-02-27
Publishing country	Greece
Document type	Case Reports ; Journal Article
ZDB-ID	807031-3
ISSN	1791-7549 ; 0258-851X
ISSN (online)	1791-7549
ISSN	0258-851X
DOI	10.21873/invivo.13526
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2288: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Long-term Survival in a Patient With Transformation of Waldenström's Macroglobulinemia into DLBCL.

Solia, Eirini / Ntanasis-Stathopoulos, Ioannis / Kastritis, Efstathios / Terpos, Evangelos / Dimopoulos, Meletios A / Gavriatopoulou, Maria

Cancer diagnosis & prognosis

2024 Volume 4, Issue 1, Page(s) 77–80

Abstract: Background/aim: Waldenström's macroglobulinemia (WM) is a rare slow-growing B-cell lymphoma that is characterized by lymphoplasmacytic bone marrow infiltration and the production of monoclonal immunoglobulin M (IgM) paraprotein. In 5-10% of patients, WM ...

Abstract	Background/aim: Waldenström's macroglobulinemia (WM) is a rare slow-growing B-cell lymphoma that is characterized by lymphoplasmacytic bone marrow infiltration and the production of monoclonal immunoglobulin M (IgM) paraprotein. In 5-10% of patients, WM undergoes transformation into diffuse large B-cell lymphoma (DLBCL), which is more aggressive, with poor prognosis and a low survival rate. Case report: Α 69-year-old woman was diagnosed with WM in 2009. She received six cycles of chemoimmunotherapy and a remarkable remission was achieved. However, in 2013 the disease transformed into DLBCL. The patient received chemotherapy and after the completion of the first cycle of therapy, the disease was significantly minimized. At the end of the therapy, there was no evidence of disease, and the patient remains disease-free. The cytogenetic profile of the patient did not reveal expression of BCL2 apoptosis regulator, BCL6 transcription repressor, Epstein-Barr virus small RNA, syndecan 1 nor cyclin D1. According to a staging system based on the platelet count, lactate dehydrogenase and previous treatment for WM, the described patient was classified as being at intermediate risk with an expected 2-year survival probability of 47% after WM transformation into DLBCL. However, the patient unexpectedly exceeded these prognostic indications. Conclusion: The findings for this patient are of great interest compared with the existing literature which suggests that the survival and prognosis for patients with transformed DLBCL are not favorable.
Language	English
Publishing date	2024-01-03
Publishing country	Greece
Document type	Journal Article
ISSN	2732-7787
ISSN (online)	2732-7787
DOI	10.21873/cdp.10289
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: A 74-Year-Old Man With Waldenström Macroglobulinemia and Progressive Dyspnea.

Tzilas, Vasilios / Nicholson, Andrew G / Gavriatopoulou, Maria / Ntanasis-Stathopoulos, Ioannis / Dimopoulos, Meletios A / Bouros, Demosthenes

Chest

2023 Volume 165, Issue 2, Page(s) e39–e43

Abstract: Case presentation: A 74-year-old man presented to our department with progressive dyspnea on exertion over the last year. The patient did not report any other symptoms. He had previously smoked with a 60 pack-year history. He worked in an office and did ...

Abstract	Case presentation: A 74-year-old man presented to our department with progressive dyspnea on exertion over the last year. The patient did not report any other symptoms. He had previously smoked with a 60 pack-year history. He worked in an office and did not report any environmental, occupational, or domestic exposures. His history included asymptomatic Waldenström's macroglobulinemia that was diagnosed 18 months before respiratory symptoms. He was not receiving any treatment and was monitored regularly by the hematology department.
MeSH term(s)	Male ; Humans ; Aged ; Waldenstrom Macroglobulinemia/complications ; Waldenstrom Macroglobulinemia/diagnosis ; Dyspnea/diagnosis ; Dyspnea/etiology
Language	English
Publishing date	2023-12-17
Publishing country	United States
Document type	Case Reports
ZDB-ID	1032552-9
ISSN	1931-3543 ; 0012-3692
ISSN (online)	1931-3543
ISSN	0012-3692
DOI	10.1016/j.chest.2023.08.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui III Zs.45: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 349: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: COVID-19 Vaccines in Patients With Cancer-A Welcome Addition, but There Is Need for Optimization.

Korompoki, Eleni / Gavriatopoulou, Maria / Kontoyiannis, Dimitrios P

JAMA oncology

2021 Volume 7, Issue 8, Page(s) 1113–1114

MeSH term(s)	Antibodies, Neutralizing/immunology ; COVID-19/immunology ; COVID-19 Vaccines/immunology ; Humans ; Neoplasms/immunology ; Neoplasms/virology ; RNA, Messenger/immunology ; SARS-CoV-2/immunology
Chemical Substances	Antibodies, Neutralizing ; COVID-19 Vaccines ; RNA, Messenger
Language	English
Publishing date	2021-08-09
Publishing country	United States
Document type	Journal Article
ISSN	2374-2445
ISSN (online)	2374-2445
DOI	10.1001/jamaoncol.2021.1218
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Small RNA-seq and clinical evaluation of tRNA-derived fragments in multiple myeloma: Loss of mitochondrial i-tRF

Soureas, Konstantinos / Papadimitriou, Maria-Alexandra / Malandrakis, Panagiotis / Papanota, Aristea-Maria / Adamopoulos, Panagiotis G / Ntanasis-Stathopoulos, Ioannis / Liacos, Christine-Ivy / Gavriatopoulou, Maria / Sideris, Diamantis C / Kastritis, Efstathios / Dimopoulos, Meletios-Athanasios / Scorilas, Andreas / Terpos, Evangelos / Avgeris, Margaritis

British journal of haematology

2024

Abstract: Despite the substantial progress in multiple myeloma (MM) therapy nowadays, treatment resistance and disease relapse remain major clinical hindrances. Herein, we have investigated tRNA-derived fragment (tRF) profiles in MM and precursor stages ( ... ...

Abstract	Despite the substantial progress in multiple myeloma (MM) therapy nowadays, treatment resistance and disease relapse remain major clinical hindrances. Herein, we have investigated tRNA-derived fragment (tRF) profiles in MM and precursor stages (smoldering MM/sMM; monoclonal gammopathy of undetermined significance/MGUS), aiming to unveil potential MM-related tRFs in ameliorating MM prognosis and risk stratification. Small RNA-seq was performed to profile tRFs in bone marrow CD138
Language	English
Publishing date	2024-02-27
Publishing country	England
Document type	Journal Article
ZDB-ID	80077-6
ISSN	1365-2141 ; 0007-1048
ISSN (online)	1365-2141
ISSN	0007-1048
DOI	10.1111/bjh.19332
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.182: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Monoclonal Gammopathy of Undetermined Cardiovascular Significance; Current Evidence and Novel Insights.

Tentolouris, Anastasios / Ntanasis-Stathopoulos, Ioannis / Gavriatopoulou, Maria / Andreadou, Ioanna / Terpos, Evangelos

Journal of cardiovascular development and disease

2023 Volume 10, Issue 12

Abstract: Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant condition characterized by the presence of low levels of a monoclonal protein in the serum and a low percentage of clonal plasma cells in the bone marrow. MGUS may progress to ... ...

Abstract	Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant condition characterized by the presence of low levels of a monoclonal protein in the serum and a low percentage of clonal plasma cells in the bone marrow. MGUS may progress to multiple myeloma or other plasma cell disorders at a rate of 1% annually. However, MGUS may also have adverse effects on the cardiovascular system independent of its malignant potential. Emerging data have shown that MGUS is associated with cardiovascular disease. The mechanisms underlying this association are not fully understood but may involve genetic abnormalities, vascular calcification, cryoglobulinemia, cold agglutinin disease, autoantibodies and the direct or indirect effects of the monoclonal protein on the vascular endothelium. Herein, we review current evidence in this field and we suggest that patients with MGUS may benefit from regular cardiovascular risk assessment to prevent severe cardiovascular complications, in parallel with close hematological follow-up to monitor potential disease progression.
Language	English
Publishing date	2023-12-04
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2777082-5
ISSN	2308-3425 ; 2308-3425
ISSN (online)	2308-3425
ISSN	2308-3425
DOI	10.3390/jcdd10120484
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma.

Fotiou, Despina / Gavriatopoulou, Maria / Terpos, Evangelos / Dimopoulos, Meletios A

Therapeutic advances in hematology

2022 Volume 13, Page(s) 20406207221090089

Abstract: Pomalidomide is a potent immunomodulatory agent that is currently a standard of care backbone for the treatment of multiple myeloma (MM) patients in the relapsed/refractory setting after exposure to lenalidomide and a proteasome inhibitor. The present ... ...

Abstract	Pomalidomide is a potent immunomodulatory agent that is currently a standard of care backbone for the treatment of multiple myeloma (MM) patients in the relapsed/refractory setting after exposure to lenalidomide and a proteasome inhibitor. The present review addresses current knowledge regarding the clinical use of pomalidomide in relapsed myeloma patients. Pomalidomide has direct myeloma cell tumoricidal effects by activating proteasomal degradation of Ikaros and Aiolos transcription factors and also indirect effects by modulation of immune responses, interaction with bone marrow stromal cells, and inhibition of angiogenesis. It is approved by regulatory authorities as doublet combination with dexamethasone but four more triplets are also approved for this setting. Many ongoing trials are evaluating the pomalidomide-dexamethasone backbone with newer anti-myeloma class agents or in quadruplet combinations. Pomalidomide-dexamethasone is currently one of the powerful tools available for use in the relapsed/refractory MM setting. Insights into the synergistic immunomodulatory effects of pomalidomide and other anti-myeloma agents and the mechanisms that overcome clonal resistance will potentially allow targeted use of triplet combinations at each relapse.
Language	English
Publishing date	2022-05-13
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2585183-4
ISSN	2040-6215 ; 2040-6207
ISSN (online)	2040-6215
ISSN	2040-6207
DOI	10.1177/20406207221090089
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Optimizing Adjuvant Therapy after Surgery for Colorectal Cancer Liver Metastases: A Systematic Review.

Georgilis, Emmanouil / Gavriatopoulou, Maria / Tsilimigras, Diamantis I / Malandrakis, Panagiotis / Theodosopoulos, Theodosios / Ntanasis-Stathopoulos, Ioannis

Journal of clinical medicine

2023 Volume 12, Issue 6

Abstract: The liver is the most common site of colorectal cancer metastatic spread. Although metastasectomy is the gold standard for fit patients with resectable colorectal cancer liver metastases (CRLMs), their management after surgical treatment remains ... ...

Abstract	The liver is the most common site of colorectal cancer metastatic spread. Although metastasectomy is the gold standard for fit patients with resectable colorectal cancer liver metastases (CRLMs), their management after surgical treatment remains controversial. The objective of this systematic review was to collate the currently available data of the agents used in the adjuvant setting in order to define the most optimal therapeutic strategy. A systematic review of the literature was conducted by searching PubMed/Medline and Cochrane library databases. We included studies that evaluated the efficacy, the tolerability and the safety profile of various chemotherapeutic agents that are used as adjuvant treatment after surgical resection of CRLMs. The outcomes of interest were regression-free survival (RFS), disease-free survival (DFS), overall survival (OS) and severe toxicities. From 543 initial articles, 29 publications with 7028 patients were finally included. In general, the results of the eligible studies indicated that adjuvant therapy after resection of CRLMs led to improved RFS/DFS rates, but this benefit did not contribute to a statistically significant prolongation of OS. Moreover, the choice of the therapeutic strategy, namely systematic or regional chemotherapy or the combination of both, did not seem to have a differential impact on patient outcomes. However, these results should be interpreted with caution since the majority of the chosen studies are of low or moderate quality. In this context, further high-quality clinical trials conducted on patient sub-populations with modern therapies are required in order to reduce in-study and between-study heterogeneity and determine which patients are expected to derive the maximum benefit from adjuvant therapy after surgery for CRLMs.
Language	English
Publishing date	2023-03-20
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2662592-1
ISSN	2077-0383
ISSN	2077-0383
DOI	10.3390/jcm12062401
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Exploring the molecular biomarker utility of circCCT3 in multiple myeloma: A favorable prognostic indicator, particularly for R-ISS II patients.

Papatsirou, Maria / Kontos, Christos K / Ntanasis-Stathopoulos, Ioannis / Malandrakis, Panagiotis / Sideris, Diamantis C / Fotiou, Despina / Liacos, Christine-Ivy / Gavriatopoulou, Maria / Kastritis, Efstathios / Dimopoulos, Meletios A / Scorilas, Andreas / Terpos, Evangelos

HemaSphere

2024 Volume 8, Issue 1, Page(s) e34

Abstract: Circular RNAs (circRNAs) are associated with the pathobiology of multiple myeloma (MM). Recent findings regarding circCCT3 support its involvement in the development and progression of MM, through microRNA sponging. Thus, we aimed to examine the ... ...

Abstract	Circular RNAs (circRNAs) are associated with the pathobiology of multiple myeloma (MM). Recent findings regarding circCCT3 support its involvement in the development and progression of MM, through microRNA sponging. Thus, we aimed to examine the expression of circCCT3 in smoldering and symptomatic MM and to assess its clinical importance. Three cell lines from plasma cell neoplasms were cultured and bone marrow aspirate (BMA) samples were collected from 145 patients with MM or smoldering MM. Next, CD138
Language	English
Publishing date	2024-01-26
Publishing country	United States
Document type	Journal Article
ISSN	2572-9241
ISSN (online)	2572-9241
DOI	10.1002/hem3.34
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study.

Gavriatopoulou, Maria / Ntanasis-Stathopoulos, Ioannis / Malandrakis, Panagiotis / Fotiou, Despina / Migkou, Magdalini / Theodorakakou, Foteini / Spiliopoulou, Vasiliki / Kanellias, Nikolaos / Eleutherakis-Papaiakovou, Evangelos / Roussou, Maria / Psarros, Giorgos / Kastritis, Efstathios / Dimopoulos, Meletios A / Terpos, Evangelos

American journal of hematology

2024 Volume 99, Issue 3, Page(s) 502–504

MeSH term(s)	Humans ; Lenalidomide/adverse effects ; Multiple Myeloma/drug therapy ; Multiple Myeloma/diagnosis ; Antibodies, Monoclonal, Humanized/therapeutic use ; Dexamethasone/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Chemical Substances	Lenalidomide (F0P408N6V4) ; belantamab mafodotin (DB1041CXDG) ; Antibodies, Monoclonal, Humanized ; Dexamethasone (7S5I7G3JQL)
Language	English
Publishing date	2024-01-25
Publishing country	United States
Document type	Clinical Trial, Phase II ; Clinical Trial, Phase I ; Letter
ZDB-ID	196767-8
ISSN	1096-8652 ; 0361-8609
ISSN (online)	1096-8652
ISSN	0361-8609
DOI	10.1002/ajh.27219
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1251: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito